Xponance Inc. Buys 216 Shares of Penumbra, Inc. (NYSE:PEN)

Xponance Inc. boosted its stake in shares of Penumbra, Inc. (NYSE:PEN) by 2.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,948 shares of the company’s stock after purchasing an additional 216 shares during the quarter. Xponance Inc.’s holdings in Penumbra were worth $1,887,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in PEN. CIBC Asset Management Inc bought a new stake in shares of Penumbra in the third quarter valued at about $218,000. Natixis Advisors LLC boosted its position in shares of Penumbra by 45.8% in the third quarter. Natixis Advisors LLC now owns 27,725 shares of the company’s stock valued at $5,387,000 after acquiring an additional 8,705 shares during the period. Advisors Asset Management Inc. boosted its position in shares of Penumbra by 11.5% in the third quarter. Advisors Asset Management Inc. now owns 416 shares of the company’s stock valued at $81,000 after acquiring an additional 43 shares during the period. Massachusetts Financial Services Co. MA bought a new stake in shares of Penumbra in the third quarter valued at about $31,965,000. Finally, Charles Schwab Investment Management Inc. boosted its position in shares of Penumbra by 1.8% in the third quarter. Charles Schwab Investment Management Inc. now owns 267,767 shares of the company’s stock valued at $52,030,000 after acquiring an additional 4,848 shares during the period. 88.88% of the stock is owned by institutional investors.

Insider Transactions at Penumbra

In other news, CFO Maggie Yuen sold 2,000 shares of the business’s stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $286.00, for a total transaction of $572,000.00. Following the sale, the chief financial officer now directly owns 15,243 shares in the company, valued at approximately $4,359,498. The trade was a 11.60 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Harpreet Grewal sold 167 shares of the business’s stock in a transaction dated Friday, January 3rd. The stock was sold at an average price of $241.28, for a total value of $40,293.76. Following the sale, the director now owns 8,530 shares in the company, valued at approximately $2,058,118.40. This trade represents a 1.92 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 81,518 shares of company stock worth $22,994,979. Insiders own 5.00% of the company’s stock.

Analyst Ratings Changes

PEN has been the subject of a number of recent research reports. Wells Fargo & Company boosted their target price on shares of Penumbra from $275.00 to $305.00 and gave the company an “overweight” rating in a research report on Wednesday, February 19th. Needham & Company LLC reaffirmed a “hold” rating on shares of Penumbra in a research note on Wednesday, February 19th. Citigroup boosted their price target on Penumbra from $220.00 to $245.00 and gave the company a “neutral” rating in a research note on Wednesday, December 11th. BTIG Research boosted their price target on Penumbra from $232.00 to $270.00 and gave the company a “buy” rating in a research note on Tuesday, November 26th. Finally, Robert W. Baird boosted their price target on Penumbra from $305.00 to $328.00 and gave the company an “outperform” rating in a research note on Wednesday, February 19th. Four investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $294.47.

Penumbra Stock Down 0.1 %

Shares of NYSE PEN opened at $280.93 on Friday. The company has a current ratio of 6.01, a quick ratio of 3.25 and a debt-to-equity ratio of 0.02. The company has a market cap of $10.82 billion, a price-to-earnings ratio of 826.25, a PEG ratio of 2.83 and a beta of 0.51. Penumbra, Inc. has a 12 month low of $148.00 and a 12 month high of $310.00. The stock has a 50-day moving average price of $272.70 and a two-hundred day moving average price of $240.30.

Penumbra (NYSE:PEN) last issued its earnings results on Tuesday, February 18th. The company reported $0.97 EPS for the quarter, topping the consensus estimate of $0.88 by $0.09. The firm had revenue of $315.52 million during the quarter, compared to the consensus estimate of $311.63 million. Penumbra had a return on equity of 9.74% and a net margin of 1.17%. As a group, analysts forecast that Penumbra, Inc. will post 3.67 earnings per share for the current fiscal year.

Penumbra Company Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.